5 Fibromyalgia Clinical Trials in Columbus, OH (2026)

Q: How do I join a clinical trial in Columbus?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbus research site will contact you.

Recruiting Fibromyalgia Studies in Columbus

NCT07357727Recruiting

A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary my...

Columbus, OHPHASE3460 participantsNovartis Pharmaceuticals

View Study Details

NCT07312734Recruiting

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is m...

Columbus, OH300 participantsChris Goss

View Study Details

NCT06343805Recruiting

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

AJX-101 is a first-in-human (FIH), phase 1, non-randomized, multi-center, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics (PK), clinical activity and chang...

Columbus, OHPHASE176 participantsAjax Therapeutics, Inc.

View Study Details

NCT07366034Recruiting

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition call...

Columbus, OHPHASE335 participantsBoehringer Ingelheim

View Study Details

NCT05835466Recruiting

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thro...

Columbus, OHPHASE210 participantsIcahn School of Medicine at Mount Sinai

View Study Details

About Fibromyalgia Clinical Trials in Columbus

Fibromyalgia is a condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties. It affects about 2-4% of the population, predominantly women. Treatment includes medications, exercise, stress management, and cognitive behavioral therapy.

There are currently 5 fibromyalgia clinical trials recruiting participants in Columbus, OH. These studies are seeking a combined 881 participants. Research is being sponsored by Novartis Pharmaceuticals, Chris Goss, Ajax Therapeutics, Inc. and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Fibromyalgia Clinical Trials in Columbus — FAQ

Are there fibromyalgia clinical trials in Columbus?

Yes, there are 5 fibromyalgia clinical trials currently recruiting in Columbus, OH. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Columbus?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbus research site will contact you about next steps.

Are clinical trials in Columbus free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Columbus studies also compensate for your time and travel.

What fibromyalgia treatments are being tested?

The 5 active trials in Columbus are testing new therapies including novel drugs, biologics, and treatment approaches for fibromyalgia.

Data updated August 28, 2026 from ClinicalTrials.gov